The Global Synthetic Biology Market was valued at USD 25.6 billion in 2025 and is estimated to grow at a CAGR of 17.5% to reach USD 128.1 billion by 2035.
Synthetic biology is revolutionizing the way we engineer biological systems by integrating engineering principles with biology to design novel biological components, devices, and systems. The field has evolved from simple genetic engineering to advanced platforms that enable precise programming of cellular functions. This transformation is driven by breakthroughs in DNA synthesis and sequencing, computational biology, and deeper insights into biological design. The market spans enabling products such as oligonucleotides, enzymes, and chassis organisms; core products including synthetic genes, cells, and DNA libraries; and enabled products covering pharmaceuticals, industrial chemicals, biofuels, and biomaterials. Cutting-edge genome editing technologies like CRISPR-Cas9 have accelerated the adoption of synthetic biology across therapeutics, agriculture, and industrial sectors, while also offering sustainable alternatives to traditional resource-intensive processes.
The enabling products segment reached USD 11.5 billion in 2025 and is expected to grow at a CAGR of 16.5% through 2035. This category includes essential tools and reagents required for synthetic biology R&D, such as oligonucleotides, enzymes like polymerases and ligases, cloning kits, chassis organisms like bacterial, yeast, and mammalian cell lines, and software platforms for design and simulation. Its dominance reflects the foundational role these products play in supporting all synthetic biology initiatives.
The pharmaceuticals and therapeutics segment reached USD 10.2 billion in 2025 and is projected to grow at a CAGR of 14.5% through 2035. This segment encompasses cell and gene therapies, mRNA vaccines, engineered biologics, and biosynthetic small molecules. Commercial and clinical validation has been achieved for multiple products, positioning pharmaceuticals and therapeutics as the most commercially advanced area of synthetic biology.
U.S. Synthetic Biology Market was valued at USD 8.6 billion in 2025 and is expected to reach USD 43.1 billion by 2035. Strong government backing supports research and development, including USD 161 million allocated by various agencies in 2020 for biomanufacturing and bioenergy, alongside USD 178 million from the Department of Energy in 2022 aimed at developing sustainable alternatives to petroleum-based products.
Leading companies in the Global Synthetic Biology Market include Novozymes, GenScript, Thermo Fisher Scientific, Ginkgo Bioworks, Twist Bioscience, Integrated DNA Technologies, ATUM, Blue Heron, Amyris, BASF, Biomax Informatics, Pareto Biotechnologies, Gevo Inc., Royal DSM, Bristol-Myers Squibb, Genomatica, Synthetic Genomics, Codexis, Butamax Scarab Genomics, MorphoSys, Evolva, and Igenbio. Key strategies adopted by synthetic biology companies to strengthen their market presence include investing heavily in research and development to create advanced, high-precision solutions, expanding product portfolios through acquisitions and strategic partnerships, and forming collaborations with academic and industrial research institutions. Companies are also focusing on scaling manufacturing capabilities, integrating AI and computational tools for better biological design, and entering emerging geographic markets to expand their global footprint.
This product will be delivered within 2-4 business days.
Synthetic biology is revolutionizing the way we engineer biological systems by integrating engineering principles with biology to design novel biological components, devices, and systems. The field has evolved from simple genetic engineering to advanced platforms that enable precise programming of cellular functions. This transformation is driven by breakthroughs in DNA synthesis and sequencing, computational biology, and deeper insights into biological design. The market spans enabling products such as oligonucleotides, enzymes, and chassis organisms; core products including synthetic genes, cells, and DNA libraries; and enabled products covering pharmaceuticals, industrial chemicals, biofuels, and biomaterials. Cutting-edge genome editing technologies like CRISPR-Cas9 have accelerated the adoption of synthetic biology across therapeutics, agriculture, and industrial sectors, while also offering sustainable alternatives to traditional resource-intensive processes.
The enabling products segment reached USD 11.5 billion in 2025 and is expected to grow at a CAGR of 16.5% through 2035. This category includes essential tools and reagents required for synthetic biology R&D, such as oligonucleotides, enzymes like polymerases and ligases, cloning kits, chassis organisms like bacterial, yeast, and mammalian cell lines, and software platforms for design and simulation. Its dominance reflects the foundational role these products play in supporting all synthetic biology initiatives.
The pharmaceuticals and therapeutics segment reached USD 10.2 billion in 2025 and is projected to grow at a CAGR of 14.5% through 2035. This segment encompasses cell and gene therapies, mRNA vaccines, engineered biologics, and biosynthetic small molecules. Commercial and clinical validation has been achieved for multiple products, positioning pharmaceuticals and therapeutics as the most commercially advanced area of synthetic biology.
U.S. Synthetic Biology Market was valued at USD 8.6 billion in 2025 and is expected to reach USD 43.1 billion by 2035. Strong government backing supports research and development, including USD 161 million allocated by various agencies in 2020 for biomanufacturing and bioenergy, alongside USD 178 million from the Department of Energy in 2022 aimed at developing sustainable alternatives to petroleum-based products.
Leading companies in the Global Synthetic Biology Market include Novozymes, GenScript, Thermo Fisher Scientific, Ginkgo Bioworks, Twist Bioscience, Integrated DNA Technologies, ATUM, Blue Heron, Amyris, BASF, Biomax Informatics, Pareto Biotechnologies, Gevo Inc., Royal DSM, Bristol-Myers Squibb, Genomatica, Synthetic Genomics, Codexis, Butamax Scarab Genomics, MorphoSys, Evolva, and Igenbio. Key strategies adopted by synthetic biology companies to strengthen their market presence include investing heavily in research and development to create advanced, high-precision solutions, expanding product portfolios through acquisitions and strategic partnerships, and forming collaborations with academic and industrial research institutions. Companies are also focusing on scaling manufacturing capabilities, integrating AI and computational tools for better biological design, and entering emerging geographic markets to expand their global footprint.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology & Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Size and Forecast, by Product Type, 2022-2035 (USD Billion)
Chapter 6 Market Size and Forecast, by Technology, 2022-2035 (USD Billion)
Chapter 7 Market Size and Forecast, by Application, 2022-2035 (USD Billion)
Chapter 8 Market Size and Forecast, by Chassis Type, 2022-2035 (USD Billion)
Chapter 9 Market Size and Forecast, by Region, 2022-2035 (USD Billion)
Chapter 10 Company Profiles
Companies Mentioned
The companies profiled in this Synthetic Biology market report include:- Novozymes
- BASF
- GenScript
- ATUM
- Integrated DNA Technologies
- Twist Bioscience
- Biomax Informatics
- Pareto Biotechnologies
- Blue Heron
- TeselaGenSyntrox
- Thermo Fisher Scientific
- Gevo Inc
- Royal DSM
- Bristol-Myers Squibb
- Amyris
- Genomatica
- Synthetic Genomics
- Codexis
- Butamax Scarab Genomics
- Scarab Genomics
- MorphoSys
- Ginkgo Bioworks
- Evolva
- Igenbio
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 210 |
| Published | January 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 25.6 Billion |
| Forecasted Market Value ( USD | $ 128.1 Billion |
| Compound Annual Growth Rate | 17.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
